Hims & Hers Health (NYSE:HIMS) Hits New 52-Week Low – Here’s Why

Hims & Hers Health, Inc. (NYSE:HIMS) shares reached a new 52-week low during trading on Thursday . The stock traded as low as $16.34 and last traded at $16.6730, with a volume of 5640362 shares trading hands. The stock had previously closed at $16.69.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Company is scaling its personalized, at‑home digital care platform with new testosterone, menopause and Labs launches and nearing ~2.5M subscribers, supporting long‑term revenue diversification. Hims & Hers Strengthens Integrated Personalized Digital Care Platform
• Positive Sentiment: Some investors/analysts view the price weakness as creating a de‑risked entry given subscriber and revenue growth trends; this view could attract value buyers if regulatory risks subside. HIMS Selloff Creates De-Risked Entry
• Neutral Sentiment: Overview piece notes HIMS has expanded into new specialties and proactive testing while revenue and subscribers grow, but flags regulatory, legal and margin pressures as risks — a mixed near‑term picture. HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell?
• Negative Sentiment: Analyst downgrade cited as pressure on the stock and contributed to intraday weakness. Hims & Hers Health (NYSE:HIMS) Stock Price Down 6% Following Analyst Downgrade
• Negative Sentiment: Major supplier/competitor (maker of Wegovy) has sued Hims & Hers over its $49 weight‑loss pill, escalating legal risk and potential damages/costs. Wegovy maker sues Hims & Hers after company launches $49 weight-loss pill
• Negative Sentiment: Company pulled the allegedly copycat GLP‑1 pill after FDA warnings/threats, showing regulatory enforcement risk and interrupted revenue from the product. Hims & Hers Pulls Copycat Wegovy Pill After FDA Threats
• Negative Sentiment: Seeking Alpha piece covers a rating downgrade and argues legal/regulatory friction is elevating uncertainty around HIMS’s GLP‑1 strategy. Hims & Hers: Does Big Pharma Always Win? (Rating Downgrade)
• Negative Sentiment: Several sell‑side firms lowered expectations or price targets (Bank of America, Citigroup, TD Cowen), increasing sell‑side negative pressure. Bank of America Has Lowered Expectations for Hims & Hers Health (NYSE:HIMS) Stock Price
• Negative Sentiment: Citigroup lowered its outlook, adding to the cluster of downgrades that pressure investor sentiment. Citigroup Has Lowered Expectations for Hims & Hers Health (NYSE:HIMS) Stock Price
• Negative Sentiment: TD Cowen issued a pessimistic forecast, further weighing on valuation expectations. TD Cowen Issues Pessimistic Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price
• Negative Sentiment: Coverage of the FDA crackdown and ensuing lawsuit underscores regulatory/legal downside risk to the GLP‑1 strategy. Hims & Hers Wegovy Knock-Off Pill Sparks Lawsuit After FDA Crackdown
• Negative Sentiment: News narratives report the weight‑loss drug strategy backfired and helped trigger a sharp one‑day stock drop, highlighting execution and PR risk. Hims & Hers Stock Plunges 24%. Its Weight-Loss Drug Strategy Backfired.
• Negative Sentiment: Coverage highlights mounting legal pressures across outlets, suggesting ongoing headline risk until litigation/regulatory outcomes are clarified. Legal pressures mount for Hims & Hers over GLP-1 sales

Wall Street Analyst Weigh In

HIMS has been the subject of a number of recent analyst reports. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Citigroup decreased their price objective on shares of Hims & Hers Health from $30.00 to $16.50 and set a “sell” rating on the stock in a report on Monday. Bank of America lowered their target price on shares of Hims & Hers Health from $26.00 to $21.00 and set an “underperform” rating on the stock in a research report on Monday. Zacks Research downgraded shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research report on Monday, January 19th. Finally, Deutsche Bank Aktiengesellschaft set a $31.00 price target on Hims & Hers Health and gave the stock a “hold” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have given a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $39.32.

Hims & Hers Health Stock Performance

The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The firm has a market capitalization of $3.58 billion, a PE ratio of 29.11, a PEG ratio of 3.02 and a beta of 2.43. The stock’s 50 day moving average price is $31.81 and its two-hundred day moving average price is $42.59.

Hims & Hers Health declared that its Board of Directors has authorized a stock repurchase plan on Monday, November 17th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the company to buy up to 3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its stock is undervalued.

Insider Activity at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $30.34, for a total transaction of $275,092.78. Following the completion of the sale, the chief financial officer directly owned 91,617 shares in the company, valued at $2,779,659.78. The trade was a 9.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Michael Chi sold 13,750 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $504,762.50. Following the sale, the chief operating officer owned 305,161 shares in the company, valued at approximately $11,202,460.31. This trade represents a 4.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 129,337 shares of company stock worth $4,651,648 over the last three months. Company insiders own 13.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds have recently made changes to their positions in the stock. VIRGINIA RETIREMENT SYSTEMS ET Al increased its holdings in shares of Hims & Hers Health by 0.8% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company’s stock worth $1,452,000 after buying an additional 200 shares during the last quarter. GAMMA Investing LLC increased its stake in Hims & Hers Health by 6.1% during the third quarter. GAMMA Investing LLC now owns 4,098 shares of the company’s stock worth $232,000 after acquiring an additional 236 shares during the last quarter. Concurrent Investment Advisors LLC increased its stake in Hims & Hers Health by 1.8% during the third quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company’s stock worth $793,000 after acquiring an additional 252 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Hims & Hers Health by 44.7% in the 3rd quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock worth $54,000 after purchasing an additional 283 shares during the period. Finally, Bessemer Group Inc. lifted its stake in shares of Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after purchasing an additional 312 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.